Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity

References

• Abraham SA, Waterhouse DN, Mayer LD, et al. (2005). The liposomal formulation of doxorubicin. Methods Enzymol 391:71–97.
   PubMed Web of Science ®Google Scholar
• Alexander J, Dainiak N, Berger HJ, et al. (1979). Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278–83.
   PubMed Web of Science ®Google Scholar
• Ataullakhanov FI, Isaev VG, Kohno AV, et al. (1997). Pharmacokinetics of doxorubicin in patients with lymphoproliferative disorders after infusion of doxorubicin-loaded erythrocytes. In Sprandel U and Way JL, eds. Erythrocytes as drug carriers in medicine. Boston, MA: Springer US, 137–142.
   Google Scholar
• Bae S, Ma K, Kim TH, et al. (2012). Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33:1536–46.
   PubMed Web of Science ®Google Scholar
• Bien S, Riad A, Ritter CA, et al. (2007). The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 67:10428–35.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Thompson PD, Martin RP, et al. (1978). Early anthracycline cardiotoxicity. Am J Med 65:823–32.
   PubMed Web of Science ®Google Scholar
• Cabrales P, Tsai AG, Intaglietta M. (2008). Modulation of perfusion and oxygenation by red blood cell oxygen affinity during acute anemia. Am J Respir Cell Mol Biol 38:354–61.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Szebeni J, Savay S, et al. (2003). Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions. Ann Oncol 14:1430–7.
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Zhang J, Honbo N, Karliner JS. (2010). Doxorubicin cardiomyopathy. Cardiology 115:155–62.
   PubMed Web of Science ®Google Scholar
• de Back DZ, Kostova EB, van Kraaij M, et al. (2014). Of macrophages and red blood cells; a complex love story. Front Physiol 5:9.
   Web of Science ®Google Scholar
• Doshi N, Zahr AS, Bhaskar S, et al. (2009). Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA 106:21495–9.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet 42:419–36.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. (1985). Liposomes for drugs and vaccines. Trends Biotechnol 3:235–41.
   Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60:277–300.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Stamp D. (1975). The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 63:651–8.
   PubMed Web of Science ®Google Scholar
• Johnson-Arbor K, Dubey R. (2018). Doxorubicin. In StatPearls. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459232/.
   Google Scholar
• Knop K, Hoogenboom R, Fischer D, Schubert US. (2010). Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 49:6288–308.
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Gabizon AA. (2017). Nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy. Front Immunol 8:416.
   Web of Science ®Google Scholar
• Li L-L, Xu J-H, Qi G-B, et al. (2014). Core–shell supramolecular gelatin nanoparticles for adaptive and ‘on-demand’ antibiotic delivery. ACS Nano 8:4975–83.
   PubMed Web of Science ®Google Scholar
• Luk BT, Zhang L. (2015). Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release off J Control Release Soc 220:600–7.
   PubMed Web of Science ®Google Scholar
• Matherne CM, Satterfield WC, Gasparini A, et al. (1994). Clinical efficacy and toxicity of doxorubicin encapsulated in glutaraldehyde-treated erythrocytes administered to dogs with lymphosarcoma. Am J Vet Res55:847–53.
   PubMed Web of Science ®Google Scholar
• Mitry MA, Edwards JG. (2016). Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Heart Vasc 10:17–24.
   PubMed Web of Science ®Google Scholar
• Muzykantov VR. (2010). Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 7:403–27.
   PubMed Web of Science ®Google Scholar
• Niu G, Cogburn B, Hughes J. (2010). Preparation and characterization of doxorubicin liposomes. Methods Mol Biol Clifton NJ 624:211–9.
   PubMedGoogle Scholar
• O’Brien MER, Wigler N, Inbar M, et al. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–9.
   PubMed Web of Science ®Google Scholar
• Oldenborg P-A, Zheleznyak A, Fang Y-F, et al. (2000). Role of CD47 as a marker of self on red blood cells. Science 288:2051–4.
   PubMed Web of Science ®Google Scholar
• Parodi A, Quattrocchi N, van de Ven AL, et al. (2013). Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotech 8:61–8.
   PubMed Web of Science ®Google Scholar
• Patnaik JL, Byers T, DiGuiseppi C, et al. (2011). Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 13:R64.
   PubMed Web of Science ®Google Scholar
• Pierigè F, Serafini S, Rossi L, Magnani M. (2008). Cell-based drug delivery. Adv Drug Deliv Rev 60:286–95.
   PubMed Web of Science ®Google Scholar
• Poste G, Bucana C, Raz A, et al. (1982). Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 42:1412–22.
   PubMed Web of Science ®Google Scholar
• Segal NH, Saltz LB. (2009). Evolving treatment of advanced colon cancer. Annu Rev Med 60:207–19.
   PubMed Web of Science ®Google Scholar
• Skorokhod OA, Kulikova EV, Galkina NM, et al. (2007). Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes. Haematologica 92:570–1.
   PubMed Web of Science ®Google Scholar
• Sun Y, Su J, Liu G, et al. (2017). Advances of blood cell-based drug delivery systems. Eur J Pharm Sci 96:115–28.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–79.
   PubMed Web of Science ®Google Scholar
• Takemura G, Fujiwara H. (2007). Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330–52.
   PubMed Web of Science ®Google Scholar
• Urva SR, Shin BS, Yang VC, Balthasar JP. (2009). Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 877:837–41.
   PubMed Web of Science ®Google Scholar
• Villela NR, Cabrales P, Tsai AG, Intaglietta M. (2009). Microcirculatory effects of changing blood hemoglobin oxygen affinity during hemorrhagic shock resuscitation in an experimental model. Shock Augusta Ga 31:645–52.
   PubMed Web of Science ®Google Scholar
• Weiss RB. (1992). The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670–86.
   PubMed Web of Science ®Google Scholar
• Xu P, Wang R, Wang X, Ouyang J. (2016). Recent advancements in erythrocytes, platelets, and albumin as delivery systems. OncoTargets Ther 9:2873–84.
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen P, Kalinowski DS, Richardson DR. (2016). Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev 68:701–87.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Su J, Ran W, et al. (2017). Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theranostics 7:2575–92.
   PubMed Web of Science ®Google Scholar
• Zheng K, Li R, Zhou X, et al. (2015). Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. Int J Nanomedicine 10:5327–42.
   PubMed Web of Science ®Google Scholar